Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

Company Overview

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an oral vitamin K antagonist designed for chronic anticoagulation in patients with implanted cardiac devices, including mechanical heart valves and left ventricular assist devices (LVADs).

Tecarfarin is intended to provide anticoagulant activity through a metabolic pathway that differs from warfarin, with the goal of reducing certain drug-drug interactions and offering a potential treatment option for patients who are difficult to manage with existing anticoagulants. Cadrenal has studied tecarfarin in patients with mechanical circulatory support devices and is advancing development for additional high-risk cardiovascular indications.

Cadrenal Therapeutics is based in the United States and was established to develop tecarfarin and related cardiovascular therapies. The company is led by Quang X. Pham, who serves as chief executive officer and chairman. Its development efforts are primarily directed toward the U.S. market and regulatory pathway, with a focus on addressing unmet needs in patients requiring durable anticoagulation.

Key Stats

• Today's Range: $0.85 to $1.01
• 50-Day Range: $0.96 to $2.09
• 52-Week Range: $0.85 to $14.64
• Volume: 149,602 shs
• Average Volume: 106,593 shs
• Market Capitalization: $3.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Hold

Cadrenal Therapeutics Stock Analysis - MarketRank™

Cadrenal Therapeutics scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cadrenal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Cadrenal Therapeutics has a consensus price target of $13.00, representing about 1,261.3% upside from its current price of $0.96.

Amount of Analyst Coverage

Cadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($3.86) to ($3.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cadrenal Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cadrenal Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cadrenal Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.90% of the float of Cadrenal Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.53, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cadrenal Therapeutics has recently increased by 36.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cadrenal Therapeutics does not currently pay a dividend.

Dividend Growth

Cadrenal Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Cadrenal Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cadrenal Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

2 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.59% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

7.92% of the stock of Cadrenal Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CVKD
• CIK: 1937993
• Web: www.cadrenal.com
• Phone: 904-300-0701
• Fax: N/A
• Employees: 5
• Year Founded: 2022

Price Target and Rating

• Average Price Target for Cadrenal Therapeutics: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +1,261.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.24 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -406.41%
• Return on Assets: -273.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.73
• Quick Ratio: 3.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.17 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 3,570,000
• Free Float: 3,047,000
• Market Cap: $3.41 million
• Optionable: Not Optionable
• Beta: 1.93